Cardiovascular events and risk factors in hematological neoplasms patients treated with anthracyclines.
10.3760/cma.j.cn112148-20220727-00584
- Author:
Meng Yuan DAI
1
;
Yan Li ZHANG
1
;
Yu Xi SUN
1
;
Xin LV
1
;
Xin Xin ZHANG
1
;
Xiu Li SUN
2
;
Feng Qi FANG
3
;
Ji Wei LIU
3
;
Yun Long XIA
1
;
Ying LIU
1
Author Information
1. Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
2. Department of Hematology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
3. Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Male;
Adult;
Middle Aged;
Aged;
Child;
Anthracyclines/adverse effects*;
Retrospective Studies;
Risk Factors;
Heart Failure/drug therapy*;
Myocardial Infarction/complications*;
Hematologic Neoplasms/complications*;
Arrhythmias, Cardiac/complications*;
Leukemia/complications*;
Hypertension/complications*
- From:
Chinese Journal of Cardiology
2022;50(11):1058-1063
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the incidence and risk factors of cardiovascular events in hematological neoplasms patients treated with anthracyclines in the real world. Methods: A total of 408 patients with lymphoma and leukemia, who were treated with anthracyclines during hospitalization in the First Affiliated Hospital of Dalian Medical University from January 1, 2018 to July 31, 2021, were included in this retrospective study. Patients were divided into cardiovascular event group (n=74) and non-cardiovascular event group (n=334). The primary endpoint was cardiovascular events (arrhythmia, heart failure, acute myocardial infarction etc.) after anthracyclines therapy. The secondary endpoint was all-cause mortality, cardiovascular-cause death, discontinued chemotherapy due to cardiovascular events. Multivariate regression analysis was used to investigate the risk factors of cardiovascular events. Kaplan-Meier was performed to calculate the incidence of all-cause mortality. Results: The mean age was (55.6±14.9) years, and there were 227 male patients (55.6%) in this cohort. The median follow-up time was 45 months. During follow-up, cardiovascular adverse events occurred in 74 patients (18.1%), including 45 heart failure (38 were heart failure with preserved ejection fraction), 30 arrhythmia, 4 acute myocardial infarction and 2 myocarditis/pericarditis. Multivariate regression analysis showed age (OR=1.024, 95%CI 1.003-1.045, P=0.027) and history of hypertension over 10 years (OR=2.328, 95%CI 1.055-5.134, P=0.036) were independent risk factors for the cardiovascular events. Kaplan-Meier survival curve showed mortality was significantly higher in cardiovascular event group than in non-cardiovascular event group (47.3% vs. 26.6%, P=0.001). In the cardiovascular event group, chemotherapy was discontinued in 9 cases (12.2%) due to cardiovascular events and cardiovascular death occurred in 7 cases (9.5%). Conclusions: Although heart failure is the main cardiovascular event in lymphoma and leukemia patients post anthracyclines therapy, other cardiovascular events especially arrhythmias are also common. The presence of cardiovascular events is associated with higher risk of all-cause mortality in these patients. Age and long-term hypertension are independent risk factors for cardiovascular events in lymphoma and leukemia patients after anthracyclines treatment.
